MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer

[1]  J. Ragaz,et al.  Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[2]  Xin Hu,et al.  Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer. , 2015, Cancer research.

[3]  M. Garg.  Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer , 2015, Expert opinion on therapeutic targets.

[4]  Y. Zeng,et al.  MiR-29c mediates epithelial-to-mesenchymal transition in human colorectal carcinoma metastasis via PTP4A and GNA13 regulation of β-catenin signaling. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Xin Hu,et al.  Liver kinase B1 enhances chemoresistance to gemcitabine in breast cancer MDA-MB-231 cells , 2014, Oncology letters.

[6]  J. Chan,et al.  The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. , 2014, Gynecologic oncology.

[7]  S. Ren,et al.  MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. , 2014, Lung cancer.

[8]  D. Fan,et al.  MicroRNAs as critical regulators involved in regulating epithelial- mesenchymal transition. , 2013, Current cancer drug targets.

[9]  Zhiwei Wang,et al.  Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway , 2013, Oncotarget.

[10]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[11]  C. Kang,et al.  AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression. , 2013, Cancer research.

[12]  Can Xu,et al.  MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. , 2013, Cancer letters.

[13]  Kun Wang,et al.  The serum miR‐21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR‐21 expression confers chemoresistance by targeting FasL , 2013, Molecular oncology.

[14]  Cheng Huang,et al.  miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. , 2013, Toxicology.

[15]  L. Qin,et al.  miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma , 2013, The Journal of experimental medicine.

[16]  G. Berx,et al.  Regulatory networks defining EMT during cancer initiation and progression , 2013, Nature Reviews Cancer.

[17]  Jing Liu,et al.  MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN , 2012, Molecular and Cellular Biochemistry.

[18]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[19]  Chang Gong,et al.  Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer* , 2011, The Journal of Biological Chemistry.

[20]  B. Zhou,et al.  Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters , 2011, BMC Cancer.

[21]  W. Hagmann,et al.  Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. , 2010, Neoplasia.

[22]  Zhiwei Wang,et al.  Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[23]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[24]  Erik W Thompson,et al.  Epithelial to mesenchymal transition and breast cancer , 2009, Breast Cancer Research.

[25]  Godefridus J Peters,et al.  Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions , 2009, Scandinavian journal of gastroenterology.

[26]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[27]  G. Gallick,et al.  Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players , 2008, Clinical Cancer Research.

[28]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[29]  J. Roh,et al.  An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. , 2007, The oncologist.

[30]  Shuomin Zhu,et al.  miR-21-mediated tumor growth , 2007, Oncogene.

[31]  Gordon B. Mills,et al.  Phosphorylation of β-Catenin by AKT Promotes β-Catenin Transcriptional Activity* , 2007, Journal of Biological Chemistry.

[32]  E. Mini,et al.  Cellular pharmacology of gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  C. Iacobuzio-Donahue,et al.  Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and Survival , 2006, Clinical Cancer Research.

[34]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[35]  L. Gelbert,et al.  An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines , 2004, Cancer Research.

[36]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[37]  Jean Paul Thiery,et al.  Epithelial-mesenchymal transitions in development and pathologies. , 2003, Current opinion in cell biology.

[38]  Godefridus J Peters,et al.  Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[39]  G. Peters,et al.  Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) , 2002 .

[40]  Guangyu Liu,et al.  Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer , 2015, International journal of cancer.

[41]  朱闻捷,et al.  MicroRNA-21 Identified as Predictor of Cancer Outcome: A Meta-Analysis , 2014 .

[42]  J. Roh,et al.  An Association Between RRM 1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients , 2007 .